<DOC>
	<DOCNO>NCT02915159</DOCNO>
	<brief_summary>The purpose study evaluate efficacy abatacept compare placebo patient Sjögren 's Syndrome .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Abatacept Adults With Active Primary Sjögrens Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com ESSDAI score least 5 Positive antiSSA/Ro antibody screen meet 2016 American College Rheumatology ( ACR ) / European League Against Rheumatism Classification Criteria Sjögren 's Syndrome ( EULAR SS ) Secondary Sjögrens syndrome Active lifethreatening organthreatening complication Sjögren'ssyndrome Other medical condition associate sicca syndrome Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>